Why Abbott Labs Stock Is a Good Buy Amid the Slump
Major Developments for Johnson & Johnson in 3Q16
Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]
Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15
Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.
Weighing in with Boston Scientific’s 4Q15 Revenues
Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.
Becton, Dickinson and Company’s 4Q16 Earnings Estimates
Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.
Chilton Investment Company buys stake in TransDigm in 4Q13
Chilton started a new position in aerospace engineering company TransDigm Group Inc. (TDG) that accounts for 0.76% of the fund’s fourth quarter portfolio.
How Has Medtronic’s Stock Performed Recently?
Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.
Emerging Markets Drive Abbott’s Nutritional Business Growth
In 1Q17, Abbott Laboratories’ (ABT) Nutritional segment reported revenue of nearly $1.6 billion, a year-over-year (or YoY) fall of ~1%.
Analysts Raise Target Prices on ABT ahead of Q3 Earnings
Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.
What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.
How Tax Reform Affected Medtronic’s 3Q18 Performance
Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]
A Look at Hologic Stock’s Recent Performance
Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.
Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
In its Structural Heart business, Abbott Laboratories reported 1Q18 sales of $0.29 billion, registering YoY organic sales growth of 7.5%.
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
Mead Johnson Plans to Focus on R&D to Support Innovations
Mead Johnson follows a strategy of investments in innovation, having expanded its liquids portfolio and rolled out its key specialty formulas across Asia.
ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.
Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.
How Are Stryker’s Core Strategies Working Toward Its Growth?
Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.
Analysts’ Recent Recommendations and Target Price for ABT Stock
On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”
Abbott Laboratories’ Stock Performance after a Recent Bull Run
On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.
European Medicines Agency Validates Merck’s Keytruda Combo
Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.
Abbott Laboratories’ Stock Price Performance in July
Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.
Trade War Fears Triggered Medtronic’s Stock Decline on March 23
Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.
How Johnson & Johnson’s Partnerships Enhance Customer Value
Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.
Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings
On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.
A Brief Look at Abbott’s Alere Integration Progress and Recovery
Alere’s integration synergies in 1Q18 were delivered through strong performance of the company’s Rapid Diagnostics business.
BSX Stock Regains Momentum after Its Recent Bearish Trend
On February 14, 2018, Boston Scientific stock closed the day at $26.81. The stock was trading near its 50-day moving average of $26.82.
A Look at Medtronic’s Recent Stock Performance
Medtronic (MDT) was trading at $83.9 on May 22, 2017. It had a 50-day moving average of $82.1 and a 200-day moving average of $78.4.
Discussing Abbott’s Market Position and Growth Prospects in China
China contributes significantly to Abbott’s Established Pharmaceuticals division, which registered sales of ~$1.1 billion, representing year-over-year growth of ~10.0%.
Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth
On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.
Boston Scientific Stock in the Week Ended September 14
Today, Boston Scientific (BSX) opened at $37.43, down ~0.51% compared to yesterday’s closing price of $37.62.
A Brief Recap of the Abbott–Alere Deal Developments
Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.
Abbott’s Freestyle Libre Gets Reimbursement Approval in France
Abbott Laboratories’ (ABT) Freestyle Libre is a sensor-based continuous glucose monitoring system that monitors and evaluates glucose levels up to 14 days.
Can Edwards Lifesciences See Robust Net Profit Margin in 2017?
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
Gilead Sciences’ COVID-19 Drug Shows Promise
Today at 7:55 AM ET, Gilead Sciences stock rose by 3.9% to $75.99 in the pre-market session. The company’s remdesivir drug might treat COVID-19.
Abbott BinaxNOW COVID-19 Test Gets FDA Approval
Chilton opens a new position in Abbott Laboratories in 4Q13
Abbott Laboratories (ABT) is a brand new position that accounts for 1.19% of Chilton’s fourth quarter 2013 portfolio.
Abbott Laboratories’s Valuation before Its 2Q16 Results
After the release of its 1Q16 earnings results on April 20, 2016, Abbott Laboratories (ABT) was trading at a forward PE multiple in the range of 16.4x–19.3x.
Examining Abiomed’s Gross Margin Trend
In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.
Understanding JNJ’s Latest Stock Price Rise
On July 20, 2017, JNJ stock was trading at its 52-week high of $137.1, which was ~25.4% above its 52-week low of $109.3 on December 7, 2016.
Behind JNJ’s Recent Stock Price Performance: Is More Growth Coming?
Johnson & Johnson (JNJ) has seen a few disappointing quarterly performances, but on October 17, when JNJ announced its 3Q17 results, the stock gained 3.4%.
What Are Analysts Estimating for Allergan Today?
AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Gilead Stock Falls, Coronavirus Drug Fails in Trial
Today at 6:07 AM ET, Gilead Sciences stock fell 1.4% to $76.70 in the pre-market session. According to reports, remdesivir failed its first clinical trial.
Abbott Laboratories Posted Its Q1 Earnings, Stock Rose 4%
At 10:07 AM ET today, Abbott Laboratories (NYSE:ABT) stock rose by about 3.9%. The company reported its first-quarter financial results.
Abbott’s Q1 Earnings Report Might Boost Its Stock
Abbott Laboratories (NYSE:ABT) stock rose by about 1.0% in extended trading on Thursday. The stock rose 1.3% and closed at $86.04.
Zoetis: An attractive business model
Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”
Chilton Investment Company buys a new stake in US Bancorp
Chilton initiated a new position in the multi-state financial holding company U.S. Bancorp (USB) that accounts for 0.92% of the fund’s fourth quarter portfolio.
Must-know market update: Is Puerto Rico losing its salsero vibe?
The charm of the island has been overshadowed with feelings of pessimism regarding the fiscally distressed state of the economy.
How Abbott Stock Reacted to the Company’s Q3 Results
Healthcare giant Abbott Laboratories announced its third-quarter earnings results before markets opened today. Its stock was trading at $83.66 midday.
These Developments Impacted Abbott Laboratories the Most in Fiscal 2017
Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.
FreeStyle Libre Is Multi-Billion Dollar Opportunity for Abbott
In the first quarter, Abbott Laboratories’ (ABT) Diabetes Care franchise reported worldwide sales of $566 million, a YoY rise of 34.4% on a reported basis.
Why Pfizer Stock Continues to Tank after Mylan Deal
Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.
How Stryker’s Margins Are Driven by Its CTG Program
Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.
How Do Rate Cuts Impact Healthcare Stocks?
Barclays expects the Fed to cut the rate by 50 basis points in July—three months earlier than previously expected. Barclays expects an additional rate cut by 25 basis points in September.
What Wall Street Recommends for Amarin after Q4 2018 Results
On February 27, Amarin (AMRN) closed at $21.18, 5.85% higher than its previous closing price, 801.28% higher than its 52-week low of $2.35, and 9.24% below its 52-week high of $23.33.
Boston Scientific or Abbott: Who Will Report More Revenue Growth?
In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%.
What Are Abbott Laboratories’ Key Growth Drivers in 2019?
On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.
What Do Analysts Recommend for Abbott Laboratories in January?
The 12-month consensus analyst recommendation for Abbott Laboratories on January 18 is a “buy.”
GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth
As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity.
Do Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.
Exploring Abiomed’s Latest Performance Trends
In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.
A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018.
How Wall Street Analysts View Medtronic in December
Of the 27 analysts tracking Medtronic in December 2018, six of them recommended a “strong buy,” while nine analysts recommended a “buy.”
Taking Stock of Edwards Lifesciences’ Performance
A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.
What Does Dentsply’s Bottom-Line Trend Indicate?
Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.
What Analysts Recommend for Hologic Stock
In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.
Analysts Remain Bullish on Stryker Stock
In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.
How Stryker Is Positioned in November
Stryker generated total revenues of $3.24 billion in the third quarter of 2018 as compared to $3.01 billion in the comparable period of 2017.
Baxter International: Why Investors Are Interested
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.
How Analysts View Alexion Stock
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.
Analyzing Alexion Pharmaceuticals’ Product Performance
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.
Merck & Co. Grows 5% in the Third Quarter
Merck & Co. (MRK) released its Q3 2018 results today, reporting net revenues of $10.8 billion, or a 5% YoY (year-over-year) growth.
Abbott Laboratories’ Nutrition Business: A Turnaround Story
Abbott Laboratories (ABT) expects its nutrition business to have low- to mid-single-digit YoY revenue growth in fiscal 2018.
Thermo Fisher Beats Analysts’ Estimates in Q3 2018 Earnings
Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.
Abbott Laboratories: Why Analysts Are So Bullish
The 12-month consensus recommendation for Abbott Laboratories on October 24 is a “buy” with a 12-month target price of $78.94.
Gauging Analysts’ Views for NovoCure Stock
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”
Zimmer Biomet Holdings: Revenue Trends ahead of Its Q3 Earnings
Zimmer Biomet (ZBH) plans to release its Q3 earnings on October 26. Analysts expect ZBH to generate third-quarter revenues of $1.8 billion.
Edwards Lifesciences’ Q3 2018 Earnings Estimates
Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.
What to Expect of Edwards Lifesciences’ Q3 2018 Sales
Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.
How Alexion Pharmaceuticals Is Positioned in October
In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.
ABT Expands in Europe with Freestyle Libre 2 Approval
On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.
ABT Stock Registered a 52-Week High in October
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.
Ionis Pharmaceuticals’ Valuations on September 28
Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.
EW Stock Returned More than the S&P 500’s Gain in 2018
As of September 28, Edwards Lifesciences (EW) has registered a rise of ~52.5% YTD (year-to-date). In the same period, the S&P 500 has risen ~9.2%.
High Valuation Multiples: Is EW Stock an Expensive Bet?
On September 27, Edwards Lifesciences was trading at a forward PE multiple of 33.2x, while its trailing 12-month PE multiple was 39.3x.
Is Abbott Laboratories Trading at a High Valuation in September?
Abbott stock has been gaining momentum recently, and its valuation has improved.
ABT Returns Almost Double the S&P 500’s Year-to-Date Gain
As of September 19, Abbott Laboratories (ABT) has registered a rise of ~17% YTD (year-to-date).
Abbott Laboratories Stock Trades at Its 52-Week High in September
On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.
Do Abiomed’s Valuations Look Attractive?
Abiomed’s (ABMD) revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018.
How Analysts View Becton Dickinson in August 2018
On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65.
What Analysts Expect from Haemonetics in Q1 2019
Haemonetics is expected to report 4.3% growth in revenues to $219.9 million during Q1 2019 as compared to $210.9 million during Q1 2018.
Analysts’ Recommendations for Hologic and Its Peers in August
Of the 19 analysts covering Hologic (HOLX) in August, five rated it as a “strong buy,” and seven rated it as a “buy.”
Analyst Recommendations for Boston Scientific and Peers in June
Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.
How Much Upside Do Analysts See in Baxter Stock?
Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.
New Trial Data Show Improved Clinical Outcomes with HeartMate3
On March 11, 2018, Abbott Laboratories (ABT) announced new late-breaking clinical trial data from its Momentum 3 study.
MitraClip Drives Growth, Gets Reimbursement Approval in Japan
On March 19, 2018, Abbott Laboratories (ABT) announced that it had received reimbursement approval for its MitraClip device in Japan.